This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL Society’s August 14 Webinar
MRD testing takes place during or after treatment to evaluate the “depth of remission” in response to therapy. Will MRD testing soon become the dominant indicator of when to stop some treatments? Join Dr. Anthony Mato as he brings us the latest thinking about the evolving role of MRD testing in CLL treatment management. CLL Society Webinar MRD: What Should It Mean to Me? on Friday, August 14 at 12:30 PM ET / 11:30 AM CT / 10:30 AM MT / 9:30 AM PT. Learn more and register here.
Test Before Treat Survey
How much do you know about the critical tests which can predict which patients will do well on or fail certain medications? Prognostic testing should be done before each and every treatment decision; share your experience and test your knowledge by completing the Test Before Treat Survey!
Save the Date!
What You Need to Know about BTK Inhibitors as Treatment for Your/Your Loved One’s CLL
On Monday, August 10th at 11AM – 12 PM EST, head to CancerCoach Live to watch an expert-led educational program that will include questions from patients, families, and caregivers about BTK inhibitors as a treatment for CLL, including:
- Identify key factors considered in selecting the right treatment for you or your loved one
- Engage with treatment teams in open dialogue to determine if BTK inhibitor treatment is right for you or your loved one’s CLL
- Discuss side effect management strategies with your treatment team
- Identify supportive resources for patients with CLL and their caregivers
Submit your questions to have them answered during the program!
Register today to save yourself a virtual seat!
This week we are continuing our coverage of the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO), which was held virtually in May. Dr. Koffman brings us number 4 of his “Top 12” CLL-relevant abstracts with short videos and accompanying text.
Dr. Koffman’s ASCO 2020 Top 12 Picks
- #4 Koffman presents a study of the long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma chronic lymphocytic leukemia (CLL).
News: Gilead has received FDA approval for CAR-T use use in mantle cell lymphoma.
Telemedicine in the COVID-19 Pandemic
Have telemedicine appointments become a part of your CLL care? Please read Dr. John Pagel’s Telemedicine: Managing Patients with CLL During the COVID-19 Pandemic. The telemedicine appointment has increased in popularity due to its advantage of making routine CLL care possible with the lowest risk of COVID-19 exposure. Dr. Pagel describes its new place in routine care and offers for tips as to how to best prepare for your telemedicine appointment. Learn more here.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
The CLL Society is invested in your long life.
Please invest in the long life of the CLL Society by investing in our work.
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.